Copper-Based Drug Could Open New Path for Alzheimer's Therapy

A copper-based drug compound is considered capable of opening a new direction in the treatment of Alzheimer’s disease. In laboratory studies, researchers reported that the compound named Cu(ATSM) was able to lower levels of toxic proteins in the brain while improving memory ability. Researchers from Monash University reported that Cu(ATSM) not only lowered levels of amyloid-beta, a protein strongly linked to Alzheimer’s, but also improved long-term spatial memory. The findings, published in ACS Chemical Neuroscience, highlight a therapeutic approach that targets the brain’s natural waste disposal system. This approach is important because in Alzheimer’s, the brain’s ability to clear harmful substances is known to decline. As a result, toxic proteins such as amyloid-beta can accumulate and disrupt cognitive function. Alzheimer’s develops partly due to the accumulation of amyloid-beta in the brain. Under normal conditions, this protein can be cleared through the blood-brain barrier, a protective layer that regulates which substances can enter and exit the brain. However, in Alzheimer’s patients, this system can become less efficient. When the clearance process weakens, harmful proteins accumulate more easily and potentially worsen brain function impairment. In this process, the P-glycoprotein pump, or P-gp, plays an important role. P-gp is a transporter protein that helps move waste from the brain into the bloodstream. When the function of this pump declines, the brain’s ability to clear toxic material also decreases. The study showed that Cu(ATSM) potentially helps restore this clearance system by increasing the quantity and activity of P-gp pumps. Lead study author Dr Jae Pyun explained that the therapy works by improving the function of brain blood vessels, thereby linking to a reduction in toxic protein levels and improved cognitive performance. “This is the first study to show that Cu(ATSM) can increase the abundance of the P-gp clearance pump in an Alzheimer’s model by 24.1 percent, effectively connecting blood-brain barrier repair with toxic protein reduction and improved cognitive function,” Dr Pyun said. The research team also reported that restoring the waste disposal pathway provided measurable impact. Over 56 days, this therapy was said to lower toxic amyloid-beta by 42 percent and improve spatial learning by nearly 44 percent. “By repairing these pumps, the brain can finally clear trapped waste,” the research team stated. These results suggest that repairing the blood-brain barrier could be one key to slowing or reducing some of the damage seen in Alzheimer’s. However, the findings are still at the laboratory stage and do not yet constitute evidence of clinical benefit in humans. Senior study author Professor Joseph Nicolazzo said Cu(ATSM) has the potential to move towards human trials faster than some other experimental therapies. The reason is that the compound has already entered clinical testing for other neurological conditions. “Cu(ATSM) is a copper compound with anti-inflammatory and neuroprotective properties that has progressed to clinical testing for conditions such as Parkinson’s and ALS,” Nicolazzo said. According to Nicolazzo, reducing the amyloid burden in the brain is a meaningful target for improving symptoms. He assessed that these preclinical results support the rationale for testing Cu(ATSM) in early-stage, symptomatic Alzheimer’s. “Because reducing amyloid burden has been clinically proven to improve functional outcomes, these preclinical results strongly support the basis for testing this drug in early symptomatic Alzheimer’s disease,” he said. Although the findings are promising, researchers still need to understand in more detail how amyloid-beta exits the brain after the blood-brain barrier is repaired. One theory suggests that Cu(ATSM) may also increase the activity of microglia, immune cells in the brain that help break down toxic proteins. Dr Dayan Goodenowe, a neuroscientist with a Ph.D. who was not directly involved in the study, assessed that targeting the blood-brain barrier and waste disposal system is a promising field. According to him, Alzheimer’s is not merely a matter of plaque storage in the brain. “Alzheimer’s involves the ageing biological environment of the brain, including membrane biology, inflammation, vascular function, lipid metabolism, and cellular resilience,” Goodenowe said. He emphasised that any single mechanism must still be validated before it can be known whether the approach truly provides meaningful clinical benefit. “The key question is not just whether amyloid changes, but whether the intervention improves cognition, function, and outcomes in humans,” he said. Goodenowe added that research needs to move from the mechanistic and preclinical stage towards evaluation of safety, dosage, efficacy, and clinical validation in humans. These findings highlight the possibility of therapeutic strategies that not only focus on amyloid-beta protein, but also on brain blood vessel function and the harmful protein clearance system. In other words, repairing the brain’s natural waste disposal system could become an important part of future Alzheimer’s therapy development. Further studies are still needed to confirm Cu(ATSM)’s mechanism of action, its safety, appropriate dosage, and whether the benefits seen in laboratory models can translate into real improvements in human patients. For now, Cu(ATSM) offers an intriguing early signal: future Alzheimer’s therapies may not only target protein accumulation, but also repair the biological systems that are supposed to clear these proteins from the brain.